31 results
6-K
EX-99.1
OBSVF
ObsEva SA
10 Dec 19
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12:00am
by Kissei R&D.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts
6-K
EX-99.1
OBSVF
ObsEva SA
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide
6-K
EX-99.1
OBSVF
ObsEva SA
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
which is sold worldwide through its licensees. KLH-2109/OBE2109 is a new chemical entity discovered by Kissei R&D.
Cautionary Note Regarding Forward
6-K
EX-99.1
OBSVF
ObsEva SA
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
” and “serving society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide
6-K
EX-99.1
OBSVF
ObsEva SA
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide in the focus fields of urology
6-K
zs8eb zxy
15 Jan 20
Current report (foreign)
8:35pm
6-K
EX-99.1
3vlz2
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
EX-99.1
7qt7z
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
o1j2pnpf28dpcid4
20 May 21
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
6:30am
6-K
EX-99.1
e8lyveuee
18 Jun 18
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS
9:17am
6-K
EX-99.1
gghns e253
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
wcv6i6c osm4y3yil
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
l5mgdcl86vu yl
28 Sep 18
Current report (foreign)
8:40am
6-K
EX-99.1
0zgd2u10
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-99.1
g7x37 1wbkqxf
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
EX-99.1
c697ons3fnn65bp4z5z
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
mi6lx260
22 Mar 22
Current report (foreign)
7:28am
6-K
2azmzwb3c656ut
7 Jun 17
Current report (foreign)
12:00am
6-K
EX-99.1
2p90yfg 4yli3dr
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.1
l3aw0yxg20v8nf0
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am